JPRN-jRCTs021180045
Recruiting
Phase 1
Phase I/II study of Gemcitabine and S-1 (GS therapy) as Neoadjuvant chemoradiationtherapy for borderline resectable pancreatic cancer (Prep-03/NS014-1)
nno Michiaki0 sites40 target enrollmentMarch 26, 2019
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Pancreatic cancer
- Sponsor
- nno Michiaki
- Enrollment
- 40
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) invasive ductal carcinoma of the pancreas
- •2\) no distant metastasis
- •3\) R0/1 resectable
- •4\) borderline resectable Pancreatic cancer
- •5\) all adult who anticipate to undergo pancreatectomy
- •6\) no prior therapy
- •7\) ECOG performance status of 0 or 1
- •8\) adequate organ function
- •9\) oral intake is possible
- •10\) written informed consent
Exclusion Criteria
- •1\) pulmonary fibrosis or interstitial pneumonitis
- •2\) Active double cancer
- •3\) Active infection
- •4\) HBs antigen positive
- •5\) patients are using flucytosine, phenytoin, warfarin
- •6\) pregnant females, possibly pregnant females
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 1
Phase I/II study of Gemcitabine and S-1 (GS therapy) as Neoadjuvant chemoradiationtherapy for borderline resectable pancreatic cancer (Prep-03/NS014-1)Borderline resectable pancreatic cancerJPRN-UMIN000014498Study group of preoperative therapy for pancreatic cancer (PREP)40
Completed
Phase 2
Phase II/III study of Gemcitabine and S-1 (GS therapy) as Neoadjuvant chemotherapy for resectable pancreatic cancer (Prep-02/JSAP-05)JPRN-UMIN000009634Study group of preoperative therapy for pancreatic cancer (PREP)/Japanese Study Group of Adjuvant Therapy for pancreatic Cancer (JSAP)364
Completed
Phase 2
Phase II study of gemcitabine/S-1 combination therapy in patients with non-resectable advanced biliary tract cancernon-resectable biliary tract cancer or recurrent biliary tract cancer post surgical treatmentJPRN-UMIN000000792Kyoto University Hospital25
Completed
Phase 2
Phase II study of gemcitabine and S-1 combination therapy in advanced pancreatic cancer with malignant ascites.pancreatic cancer with ascitesJPRN-UMIN000003269ational Cancer Center Hospital East Hepatobiliary and Pancreatic Oncology Division36
Completed
Phase 2
Randomized phase II study of Gemcitabine and S-1 combination therapy versus S-1 in patients with Gemcitabine-refractory unresectable advanced Pancreatic Cancerunresectable advanced Pancreatic CancerJPRN-UMIN000011806Osaka Pancreas Forum49